# ChartGlucose4Moms: Characterizing by Trimester, Continuous Glucose Monitoring Measurements for determining effects on Maternal & Offspring Metabolic Sequelae

> **NIH NIH U01** · KAISER FOUNDATION RESEARCH INSTITUTE · 2024 · $48,600

## Abstract

Protocol Summary/Abstract
In the setting of increasing prevalence of obesity and pre-diabetes, there is growing interest in identification of
hyperglycemia in early pregnancy to facilitate treatment and minimize fetal exposure. Although multiple
organizations recommend first trimester diabetes screening among individuals with risk factors, the benefits
and drawbacks of detecting glucose abnormalities short of frank diabetes and optimal screening method in
early gestation remain unclear. The overarching goal of the NIDDK-supported ChartGlucose4Moms:
Characterizing, by Trimester, Continuous Glucose Monitoring Measurements for determining effects on
Maternal & Offspring Metabolic Sequelae study (aka, Glycemic Observation and Metabolic Outcomes in
Mothers and offspring (GO MOMs) study) is to evaluate how early pregnancy glycemia, measured using
continuous glucose monitoring (CGM) and oral glucose tolerance testing (OGTT), relates to gestational
diabetes (GDM) diagnosis at 24-28 weeks' gestation (maternal primary outcome) and large-for-gestational-age
(newborn primary outcome). A secondary objective is to perform comprehensive, longitudinal assessment of
changes in glucose over the course of pregnancy. Enrollment began in April 2021 and will continue for 3.5
years with a target sample size of 2150 participants (200 of which are being recruited at KPNW). GO MOMs
will yield data that are vital to improving our understanding of hyperglycemia in pregnancy, facilitate improved
approaches for GDM screening in early pregnancy, and inform future clinical trials of early GDM treatment.

## Key facts

- **NIH application ID:** 11160289
- **Project number:** 3U01DK123791-05S1
- **Recipient organization:** KAISER FOUNDATION RESEARCH INSTITUTE
- **Principal Investigator:** ERIN S LEBLANC
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $48,600
- **Award type:** 3
- **Project period:** 2019-09-20 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11160289

## Citation

> US National Institutes of Health, RePORTER application 11160289, ChartGlucose4Moms: Characterizing by Trimester, Continuous Glucose Monitoring Measurements for determining effects on Maternal & Offspring Metabolic Sequelae (3U01DK123791-05S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11160289. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*